Latest News
Korro Bio, Inc.
- Korro Bio reports KRRO-111 preclinical data in AATD
- KRRO-111 achieves 95 percent reduction in liver Z-AAT, Korro Bio unveils new preclinical data
- Form 8K Korro Bio Inc For: 22 October By Investing.com
- Korro Bio reports preclinical data for AATD treatment KRRO-111 By Investing.com
- Korro Bio at Chardan’s 10th Annual Healthcare Conference: RNA push By Investing.com
- Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Two new hires can earn the right to buy Korro Bio shares over four years.
- Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?
- Korro Bio to present new RNA editing chemistries at OTS2026 in Denver
- H.C. Wainwright reiterates Korro Bio stock rating on trial dosing
- Korro Bio doses first patients in urea cycle disorder trial
Headlines from the last 30 days, linking to the original publishers. See all market news →